Innovative engineering of CAR‐T cells through metabolic reprogramming strategies—such as enhancing lipolysis via PPAR‐γ overexpression—combined with modifications of tumor‐homing receptors, exemplified by CXCR2‐targeted localization in fibrotic tumors, has shown breakthrough therapeutic potential in preclinical investigations.[185, 186, 187, 188] In terms of safety, closed‐loop control systems have emerged as crucial strategies for mitigating CRS and neurotoxicity. The gene discussed is CXCR2; the disease is neoplasm.